JNJ Insider Transactions
Transaction Date (SEC Report) |
Reporting Name | Relationship | Shrs. Owned | Type | Acq./Disp. | Shrs. Transacted | Price() | Amount() |
---|---|---|---|---|---|---|---|---|
2024-04-25 | Beckerle Mary C | director | 13,643.012 | A-Award | A | 1,385.697 | 0.00 | 0.00 |
2024-04-25 | HEWSON MARILLYN A | director | 10,173.4414 | A-Award | A | 1,385.697 | 0.00 | 0.00 |
2024-04-25 | West Nadja | director | 5,093.682 | A-Award | A | 1,385.697 | 0.00 | 0.00 |
2024-04-25 | Adamczyk Darius | director | 3,712.704 | A-Award | A | 1,385.697 | 0.00 | 0.00 |
2024-04-25 | Woods Eugene A. | director | 2,139.143 | A-Award | A | 1,385.697 | 0.00 | 0.00 |
2024-04-25 | MULCAHY ANNE M | director | 21,470.618 | A-Award | A | 1,385.697 | 0.00 | 0.00 |
2024-04-25 | McClellan Mark B. | director | 17,867.715 | A-Award | A | 1,385.697 | 0.00 | 0.00 |
2024-04-25 | WEINBERGER MARK A | director | 9,129.352 | A-Award | A | 1,385.697 | 0.00 | 0.00 |
2024-04-25 | Joly Hubert | director | 6,464.145 | A-Award | A | 1,385.697 | 0.00 | 0.00 |
2024-04-25 | Johnson Paula A | director | 2,858.548 | A-Award | A | 1,385.697 | 0.00 | 0.00 |
2024-04-25 | Doudna Jennifer A | director | 8,081.638 | A-Award | A | 1,385.697 | 0.00 | 0.00 |
2024-03-13 | Broadhurst Vanessa | officer: EVP, Global Corp Affairs | 15,043 | S-Sale | D | 8,891 | 162.16 | 1,441,765.00 |
2024-03-05 | Woods Eugene A. | director | 753.446 | A-Award | A | 261.993 | 0.00 | 0.00 |
2024-03-05 | Woods Eugene A. | director | 491.453 | A-Award | A | 491.453 | 0.00 | 0.00 |
2024-03-05 | HEWSON MARILLYN A | director | 8,787.7444 | A-Award | A | 234.6683 | 0.00 | 0.00 |
2024-02-15 | Taubert Jennifer L | officer: EVP, WWC. Innovative Medicine | 76,981 | A-Award | A | 76,981 | 157.92 | 12,156,840.00 |
2024-02-15 | Taubert Jennifer L | officer: EVP, WWC. Innovative Medicine | 4,782 | A-Award | A | 4,782 | 0.00 | 0.00 |
2024-02-15 | Wengel Kathryn E | officer: EVP, Chief TO and Risk Officer | 29,275 | A-Award | A | 29,275 | 157.92 | 4,623,108.00 |
2024-02-15 | Wengel Kathryn E | officer: EVP, Chief TO and Risk Officer | 1,819 | A-Award | A | 1,819 | 0.00 | 0.00 |
2024-02-15 | Schmid Timothy | officer: EVP, WW Chair, MedTech | 49,658 | A-Award | A | 49,658 | 157.92 | 7,841,991.00 |
2024-02-15 | Schmid Timothy | officer: EVP, WW Chair, MedTech | 3,085 | A-Award | A | 3,085 | 0.00 | 0.00 |
2024-02-15 | Hait William | officer: EVP, Chief EI and Med Officer | 34,696 | A-Award | A | 34,696 | 157.92 | 5,479,192.00 |
2024-02-15 | Hait William | officer: EVP, Chief EI and Med Officer | 2,155 | A-Award | A | 2,155 | 0.00 | 0.00 |
2024-02-15 | Swanson James D. | officer: EVP, CIO | 23,745 | A-Award | A | 23,745 | 157.92 | 3,749,810.00 |
2024-02-15 | Swanson James D. | officer: EVP, CIO | 1,475 | A-Award | A | 1,475 | 0.00 | 0.00 |
2024-02-15 | REED JOHN C | officer: EVP, Innovative Medicine, R&D | 65,163 | A-Award | A | 65,163 | 157.92 | 10,290,541.00 |
2024-02-15 | REED JOHN C | officer: EVP, Innovative Medicine, R&D | 4,048 | A-Award | A | 4,048 | 0.00 | 0.00 |
2024-02-15 | Wolk Joseph J | officer: Exec VP, CFO | 95,197 | A-Award | A | 95,197 | 157.92 | 15,033,510.00 |
2024-02-15 | Wolk Joseph J | officer: Exec VP, CFO | 5,913 | A-Award | A | 5,913 | 0.00 | 0.00 |
2024-02-15 | Forminard Elizabeth | officer: Executive VP, General Counsel | 46,406 | A-Award | A | 46,406 | 157.92 | 7,328,436.00 |
2024-02-15 | Forminard Elizabeth | officer: Executive VP, General Counsel | 2,883 | A-Award | A | 2,883 | 0.00 | 0.00 |
2024-02-15 | Duato Joaquin | director, officer: CEO and Chairman of the Board | 177,816 | A-Award | A | 177,816 | 157.92 | 28,080,703.00 |
2024-02-15 | Duato Joaquin | director, officer: CEO and Chairman of the Board | 11,046 | A-Award | A | 11,046 | 0.00 | 0.00 |
2024-02-15 | Fasolo Peter | officer: Exec VP, Chief HR Officer | 40,551 | A-Award | A | 40,551 | 157.92 | 6,403,814.00 |
2024-02-15 | Fasolo Peter | officer: Exec VP, Chief HR Officer | 2,519 | A-Award | A | 2,519 | 0.00 | 0.00 |
2024-02-15 | Broadhurst Vanessa | officer: EVP, Global Corp Affairs | 23,745 | A-Award | A | 23,745 | 157.92 | 3,749,810.00 |
2024-02-15 | Broadhurst Vanessa | officer: EVP, Global Corp Affairs | 1,475 | A-Award | A | 1,475 | 0.00 | 0.00 |
2024-02-15 | Decker Robert J | officer: VP Corporate Controller | 8,175 | A-Award | A | 8,175 | 157.92 | 1,290,996.00 |
2024-02-15 | Decker Robert J | officer: VP Corporate Controller | 1,016 | A-Award | A | 1,016 | 0.00 | 0.00 |
2024-02-13 | Wengel Kathryn E | officer: EVP, Chief TO and Risk Officer | 82,598.8735 | M-Exempt | A | 651 | 0.00 | 0.00 |
2024-02-13 | Wengel Kathryn E | officer: EVP, Chief TO and Risk Officer | 82,265.8735 | F-InKind | D | 333 | 157.85 | 52,564.00 |
2024-02-13 | Wengel Kathryn E | officer: EVP, Chief TO and Risk Officer | 1,302 | M-Exempt | D | 651 | 0.00 | 0.00 |
2024-02-13 | Wolk Joseph J | officer: Exec VP, CFO | 69,663 | M-Exempt | A | 1,780 | 0.00 | 0.00 |
2024-02-13 | Wolk Joseph J | officer: Exec VP, CFO | 68,890 | F-InKind | D | 773 | 157.85 | 122,018.00 |
2024-02-13 | Wolk Joseph J | officer: Exec VP, CFO | 3,558 | M-Exempt | D | 1,780 | 0.00 | 0.00 |
2024-02-13 | Taubert Jennifer L | officer: EVP, WWC. Innovative Medicine | 155,517.001 | M-Exempt | A | 1,302 | 0.00 | 0.00 |
2024-02-13 | Taubert Jennifer L | officer: EVP, WWC. Innovative Medicine | 154,851.001 | F-InKind | D | 666 | 157.85 | 105,128.00 |
2024-02-13 | Taubert Jennifer L | officer: EVP, WWC. Innovative Medicine | 2,604 | M-Exempt | D | 1,302 | 0.00 | 0.00 |
2024-02-13 | Swanson James D. | officer: EVP, CIO | 14,765 | M-Exempt | A | 447 | 0.00 | 0.00 |
2024-02-13 | Swanson James D. | officer: EVP, CIO | 14,570 | F-InKind | D | 195 | 157.85 | 30,781.00 |
2024-02-13 | Swanson James D. | officer: EVP, CIO | 894 | M-Exempt | D | 447 | 0.00 | 0.00 |
2024-02-13 | Schmid Timothy | officer: EVP, WW Chair, MedTech | 13,290 | M-Exempt | A | 499 | 0.00 | 0.00 |
2024-02-13 | Schmid Timothy | officer: EVP, WW Chair, MedTech | 13,040 | F-InKind | D | 250 | 157.85 | 39,462.00 |
2024-02-13 | Schmid Timothy | officer: EVP, WW Chair, MedTech | 998 | M-Exempt | D | 499 | 0.00 | 0.00 |
2024-02-13 | Fasolo Peter | officer: Exec VP, Chief HR Officer | 112,550 | M-Exempt | A | 925 | 0.00 | 0.00 |
2024-02-13 | Fasolo Peter | officer: Exec VP, Chief HR Officer | 112,076 | F-InKind | D | 474 | 157.85 | 74,821.00 |
2024-02-13 | Fasolo Peter | officer: Exec VP, Chief HR Officer | 1,848 | M-Exempt | D | 925 | 0.00 | 0.00 |
2024-02-13 | Hait William | officer: See Remarks | 39,074 | M-Exempt | A | 834 | 0.00 | 0.00 |
2024-02-13 | Hait William | officer: See Remarks | 38,647 | F-InKind | D | 427 | 157.85 | 67,402.00 |
2024-02-13 | Hait William | officer: See Remarks | 1,666 | M-Exempt | D | 834 | 0.00 | 0.00 |
2024-02-13 | Duato Joaquin | director, officer: CEO and Chairman of the Board | 364,809 | M-Exempt | A | 3,470 | 0.00 | 0.00 |
2024-02-13 | Duato Joaquin | director, officer: CEO and Chairman of the Board | 363,302 | F-InKind | D | 1,507 | 157.85 | 237,880.00 |
2024-02-13 | Duato Joaquin | director, officer: CEO and Chairman of the Board | 6,939 | M-Exempt | D | 3,470 | 0.00 | 0.00 |
2024-02-13 | Broadhurst Vanessa | officer: EVP, Global Corp Affairs | 24,143 | M-Exempt | A | 408 | 0.00 | 0.00 |
2024-02-13 | Broadhurst Vanessa | officer: EVP, Global Corp Affairs | 23,934 | F-InKind | D | 209 | 157.85 | 32,991.00 |
2024-02-13 | Forminard Elizabeth | officer: Executive VP, General Counsel | 8,576 | M-Exempt | A | 651 | 0.00 | 0.00 |
2024-02-13 | Forminard Elizabeth | officer: Executive VP, General Counsel | 8,340 | F-InKind | D | 236 | 157.85 | 37,253.00 |
2024-02-13 | Forminard Elizabeth | officer: Executive VP, General Counsel | 1,302 | M-Exempt | D | 651 | 0.00 | 0.00 |
2024-02-13 | Broadhurst Vanessa | officer: EVP, Global Corp Affairs | 816 | M-Exempt | D | 408 | 0.00 | 0.00 |
2024-02-13 | Decker Robert J | officer: VP Corporate Controller | 19,059 | M-Exempt | A | 313 | 0.00 | 0.00 |
2024-02-13 | Decker Robert J | officer: VP Corporate Controller | 18,973 | F-InKind | D | 86 | 157.85 | 13,575.00 |
2024-02-13 | Decker Robert J | officer: VP Corporate Controller | 624 | M-Exempt | D | 313 | 0.00 | 0.00 |
2024-02-12 | Broadhurst Vanessa | officer: EVP, Global Corp Affairs | 25,871 | A-Award | A | 790 | 0.00 | 0.00 |
2024-02-12 | Broadhurst Vanessa | officer: EVP, Global Corp Affairs | 25,081 | M-Exempt | A | 4,701 | 0.00 | 0.00 |
2024-02-12 | Broadhurst Vanessa | officer: EVP, Global Corp Affairs | 23,735 | F-InKind | D | 2,136 | 157.40 | 336,206.00 |
2024-02-12 | Broadhurst Vanessa | officer: EVP, Global Corp Affairs | 0 | M-Exempt | D | 4,701 | 0.00 | 0.00 |
2024-02-12 | Hait William | officer: See Remarks | 42,316 | M-Exempt | A | 1,285 | 0.00 | 0.00 |
2024-02-12 | Hait William | officer: See Remarks | 41,031 | M-Exempt | A | 7,647 | 0.00 | 0.00 |
2024-02-12 | Hait William | officer: See Remarks | 38,240 | F-InKind | D | 4,076 | 157.40 | 641,562.00 |
2024-02-12 | Hait William | officer: See Remarks | 0 | M-Exempt | D | 7,647 | 0.00 | 0.00 |
2024-02-12 | Wolk Joseph J | officer: Exec VP, CFO | 78,699 | M-Exempt | A | 3,716 | 0.00 | 0.00 |
2024-02-12 | Wolk Joseph J | officer: Exec VP, CFO | 74,983 | M-Exempt | A | 22,119 | 0.00 | 0.00 |
2024-02-12 | Wolk Joseph J | officer: Exec VP, CFO | 67,883 | F-InKind | D | 10,816 | 157.40 | 1,702,438.00 |
2024-02-12 | Wolk Joseph J | officer: Exec VP, CFO | 0 | M-Exempt | D | 22,119 | 0.00 | 0.00 |
2024-02-12 | Forminard Elizabeth | officer: Executive VP, General Counsel | 8,959 | M-Exempt | A | 411 | 0.00 | 0.00 |
2024-02-12 | Forminard Elizabeth | officer: Executive VP, General Counsel | 8,548 | M-Exempt | A | 2,448 | 0.00 | 0.00 |
2024-02-12 | Forminard Elizabeth | officer: Executive VP, General Counsel | 7,925 | F-InKind | D | 1,034 | 157.40 | 162,752.00 |
2024-02-12 | Forminard Elizabeth | officer: Executive VP, General Counsel | 0 | M-Exempt | D | 2,448 | 0.00 | 0.00 |
2024-02-12 | Taubert Jennifer L | officer: EVP, WWC. Innovative Medicine | 167,618.001 | M-Exempt | A | 3,769 | 0.00 | 0.00 |
2024-02-12 | Taubert Jennifer L | officer: EVP, WWC. Innovative Medicine | 163,849.001 | M-Exempt | A | 22,433 | 0.00 | 0.00 |
2024-02-12 | Taubert Jennifer L | officer: EVP, WWC. Innovative Medicine | 154,215.001 | F-InKind | D | 13,403 | 157.40 | 2,109,632.00 |
2024-02-12 | Taubert Jennifer L | officer: EVP, WWC. Innovative Medicine | 0 | M-Exempt | D | 22,433 | 0.00 | 0.00 |
2024-02-12 | Fasolo Peter | officer: Exec VP, Chief HR Officer | 118,644 | M-Exempt | A | 2,152 | 0.00 | 0.00 |
2024-02-12 | Fasolo Peter | officer: Exec VP, Chief HR Officer | 116,492 | M-Exempt | A | 12,808 | 0.00 | 0.00 |
2024-02-12 | Fasolo Peter | officer: Exec VP, Chief HR Officer | 111,625 | F-InKind | D | 7,019 | 157.40 | 1,104,791.00 |
2024-02-12 | Fasolo Peter | officer: Exec VP, Chief HR Officer | 0 | M-Exempt | D | 12,808 | 0.00 | 0.00 |
2024-02-12 | Swanson James D. | officer: EVP, CIO | 16,013 | M-Exempt | A | 785 | 0.00 | 0.00 |
2024-02-12 | Swanson James D. | officer: EVP, CIO | 15,228 | M-Exempt | A | 4,671 | 0.00 | 0.00 |
2024-02-12 | Swanson James D. | officer: EVP, CIO | 14,318 | F-InKind | D | 1,695 | 157.40 | 266,793.00 |
2024-02-12 | Swanson James D. | officer: EVP, CIO | 0 | M-Exempt | D | 4,671 | 0.00 | 0.00 |
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.